Da har toget tatt av stasjonen, spent på hvor det ender i denne omgangen 
tut tut
Fine 10% om dagen nå på brukbart volum 
»Ingen ved om Bavarian Nordics viser sig at lykkes med, hvad de indledende håber, og ingen ved om de andre vacciner i større studier ikke er bedre end de foregående. Men hvis og kun hvis: Bavarian Nordic lykkes med sit forehavende kan mulighederne for at de har den universelle boostervaccine, som kan blive en form for standard, være gode,« mener Per Hansen.
EXPRES2ION BIOTECHNOLOGIES
ExpreS2ion Announces Formation of Oncology Scientific Advisory Board (Cision)
2022-11-03 10:30
Hørsholm, Denmark, November 3, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces the establishment of an Oncology Scientific Advisory Board (OSAB). The six initial members of the ExpreS2ion OSAB bring a depth of knowledge in oncology, breast cancer, clinical trials and therapeutic HER2 vaccines, and will contribute to the development of ExpreS2ion’s proprietary HER2-cVLP breast cancer vaccine, ES2B-C001. The OSAB will serve as advisors, potential contributors to the planned clinical studies and participants in Key Opinion Leader events for the scientific community and investors.
Chief Executive Officer Bent Frandsen comments:
“It is with considerable pride that we announce the establishment of our Oncology Scientific Advisory Board, comprised of six renowned scientists whom I am confident will facilitate the development of ES2B-C001 in a manner that optimizes its potential. As ES2B-C001 gains momentum on its progress towards clinical development, ExpreS2ion is at a critical juncture in which the OSAB will augment the Company’s already deep R&D competencies. On behalf of ExpreS2ion, I welcome our new OSAB members to the ExpreS2ion story and look forward to developing a therapy that will potentially benefit women suffering from HER2-expressing breast cancer worldwide.”
Initial trial results are expected in the early part of 2023, which is a slight delay from the original plan due to a delayed recruitment initiation caused by late regulatory challenges and logistics associated with the comparator vaccine.
Tror bava har 0/0 treff på guidingen sin når det gjelder covid vaksinen 
Nano vibber 
Readout kan komme når som helst nå.
Gode data mot flere varianter.
1 stikk holder i lang tid, muligens flere år.
Vaksinen kan lagres i kjøleskap. Ingen behov for å fryses.
Ingen adjuvant. Mindre bivirkninger.
Aksjen har steget 70% på noen måneder nå. Dog falt mye fra toppen.
Posisjonering inc mot phase III readout.
I am truly excited to join Bent and his team of highly skilled scientists, who have developed one of the currently most exciting pipelines in the biotech industry with unique vaccine candidates to prevent COVID-19 and treat breast cancer. I am looking forward to create further value out of ExpreS2ion’s vaccine technology platform.”
“This is the first year ExpreS[2]ion will participate in the annual J.P. Morgan Healthcare Conference and the associated Biotech Showcase. We are looking forward to introducing ExpreS[2]ion’s pipeline and platform to a new global audience, obtaining inspiration from the world’s leading healthcare companies, and expanding our network at the world’s largest annual healthcare investment symposium,” says CEO Bent Frandsen.
Another one bites the dust.
Det frister å ta et bet her pga kursfallet, bava ceo uttalte allerede i januar i et intervju om sen rekruttering. Men som alltid reagerer markedet hardere ved en PM.
Når det kommer til expres2ion så er det ikke mye penger igjen i kassa, og nå som utsettelsen er godt over 6mnd på overtid så kan det lugge til med en emisjon før royalties går til expres2ion.
Det eneste som kan dra kursen før studien er fullt innrullert og data avlest, er forhånds bestillinger av vaksinen tenker jeg.
Men med tanke på dagens covid situasjon så er hypen over og det ser ut til at både expres2ion og bava er late 2 the party
12mndr data fra fase2 studien kan kanskje redde det inn om det viser seg at varigheten av beskyttelsen er god 
Bava står til stryk er min mening
Pareto sier de ikke kommer med en oppdatering etter meldingen onsdag. Det har kanskje sammenheng med at de har tatt ned bidraget fra COVID-vaksinen tidligere. Siste fra de er TP 25.
Fornuftig nå å avvente hvordan de løser finansene. Det er vel et stykke frem til andre produktinntekter og ev royalties? Kan de finne på å selge AdaptVac andelen?
PAS: Rights issue of up to SEK 102m to be proposed at 23 March EGM
On 3 March, the company announced a proposed rights issue that would result in initial gross proceeds of between SEK 51m and SEK 102m in mid-April, with scope for additional proceeds of a similar order of magnitude in connection with the exercise of linked warrants. The proceeds will be used to finance the further development of the breast cancer vaccine candidate ES2B-C001, a key value driver expected to be phase I-ready towards year-end, and to invest into the company’s platform technology and pipeline expansion. The proposed measures are consistent with previous communication and decrease ExpreS2ion’s reliance on potential future cash flows from ABNCoV2 (COVID-19, phase III). We rate the shares a Buy as we regard ABNCoV2 and ES2B-C001 as under-rated by the market and note scope for accelerated maturation of the pre-clinical pipeline in the event of a successful rights issue.
Det er vel bare å vente til støvet har lagt seg …
… lugter all time low her.
Ser Discorden mener garantistene betaler 4,9 SEK. Da skal den vel dit i løpet av april?